Encouraging results were observed with the epidermal growth factor receptor (EGFR) where 89Zr-cetuximab (86) has provided additional information on advanced head and neck cancer (ARTFORCE study, Clinicaltrials.gov identifier NCT 01504815) for an enlightened choice of the most effective treatment between cisplatin or cetuximab (87, 88). This evidence concerns the gene EGFR and head and neck cancer.